SHPH Stock Price, Shuttle Pharmaceuticals Holdings Quote, Chart

Market Summary

USD0.410.00

Delayedas of 17 May 2024, 12:30 pm

0.00%

SHPH Stock Price

View Fullscreen

SHPH RSI Chart

SHPH Valuation

Market Cap

6.9M

Price/Earnings (Trailing)

-0.94

EV/EBITDA

-1.09

Price/Free Cashflow

-1.25

MarketCap/EBT

-1.34

SHPH Price/Earnings (Trailing)

SHPH Profitability

Return on Equity

-264.99%

Return on Assets

-153.93%

Free Cashflow Yield

-79.89%

SHPH Fundamentals

SHPH Earnings

Earnings (TTM)

-7.3M

Earnings Growth (Yr)

-74.34%

Earnings Growth (Qtr)

-3.63%

Breaking Down SHPH Revenue

52 Week Range

0.41

(Low)(High)

Last 7 days

-2.4%

Last 30 days

-2.4%

Last 90 days

7.9%

How does SHPH drawdown profile look like?

SHPH Financial Health

Current Ratio

2.96

SHPH Investor Care

Shares Dilution (1Y)

23.00%

Diluted EPS (TTM)

-0.47

Tracking the Latest Insider Buys and Sells of Shuttle Pharmaceuticals Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 08, 2024	vander hoek michael	acquired	-	-	100,000	chief financial officer
Dec 13, 2023	jacobs bette	sold	-1,925	0.4632	-4,157	-
Dec 13, 2023	brown milton	sold	-1,353	0.4632	-2,921	-
Aug 14, 2023	dritschilo anatoly	gifted	-	-	-2,100,000	ceo and chairman
Aug 14, 2023	dritschilo anatoly	gifted	-	-	2,100,000	ceo and chairman
Dec 29, 2022	dritschilo peter	sold	-18,393	1.605	-11,460	president and coo
Dec 29, 2022	dritschilo anatoly	sold	-13,437	1.605	-8,372	ceo and chairman
Dec 29, 2022	brown milton	sold	-1,596	1.605	-995	-
Dec 29, 2022	rich tyvin	sold	-2,269	1.605	-1,414	chief medical officer
Dec 29, 2022	jung mira	sold	-526	1.605	-328	chief scientific officer

Which funds bought or sold SHPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	151	56.00	102	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	406	406	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-41.9	-6,000	7,000	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-1,449	15,004	-%
May 13, 2024	UBS Group AG	new	-	455	455	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	1.89	-2.00	22.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	StoneX Group Inc.	sold off	-100	-23,000	-	-%
Feb 26, 2024	Virtu Financial LLC	new	-	9,000	9,000	-%
Nov 13, 2023	Ayrton Capital LLC	reduced	-12.15	-154,092,000	134,460,000	0.91%

Are Funds Buying or Selling SHPH?

Are funds buying SHPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SHPH

No. of Funds

Unveiling Shuttle Pharmaceuticals Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 18, 2023	afh holding & advisory, llc	3.80%	597,149	SC 13G/A

Recent SEC filings of Shuttle Pharmaceuticals Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
Apr 29, 2024	8-K	Current Report
Apr 23, 2024	8-K	Current Report
Apr 05, 2024	S-1	Initial Public Offering
Mar 22, 2024	8-K	Current Report
Mar 22, 2024	424B3	Prospectus Filed
Mar 21, 2024	10-K	Annual Report
Mar 14, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to Shuttle Pharmaceuticals Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	371.3B	85.6B	6.80%	-2.97%	9.65	4.33	5.68%	202.39%
MRK	331.6B	61.4B	4.69%	14.08%	143.8	5.4	6.11%	-82.30%
AMGN	168.9B	29.5B	18.50%	39.89%	44.87	5.72	12.76%	-52.47%
PFE	163.9B	57.8B	12.61%	-21.28%	130.78	2.84	76.51%	-86.81%
GILD	84.6B	27.4B	0.85%	-13.87%	174.55	3.08	1.51%	-91.32%
TEVA	18.5B	16.0B	24.52%	100.49%	-37.33	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	2.99%	-21.03%	9.53	2.4	54.01%	364.56%
PRGO	4.1B	4.6B	0.47%	-8.40%	-532.89	0.9	-0.06%	94.55%
BHC	2.6B	9.0B	-19.11%	-5.35%	-5.7	0.29	10.01%	-27.45%
AMPH	2.1B	676.2M	4.47%	-0.56%	13.51	3.09	30.38%	66.04%
SMALL-CAP
TLRY	1.6B	743.2M	16.39%	-11.62%	-4.68	2.22	24.65%	80.36%
TXMD	24.2M	1.3M	10.53%	-49.88%	-3.27	18.6	-98.14%	-104.71%
ACRX	19.7M	89.6M	13.73%	58.80%	-1.39	0.19	287.27%	-129.41%
AGRX	2.6M	21.5M	2.56%	-90.89%	-0.34	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Shuttle Pharmaceuticals Holdings Inc News

Latest updates

Shuttle Pharmaceuticals Holdings Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-20.1%	4,754	5,952	7,376	8,837	10,437	8,654	9,382	6,472	3,562	652	544
Current Assets	-21.1%	4,411	5,593	6,996	8,443	10,372	8,578	9,289	-	-	510	341
Cash Equivalents	-45.7%	1,399	2,576	3,886	5,447	7,169	8,417	9,120	-	-	505	117
Net PPE	-7.7%	23.00	25.00	27.00	10.00	11.00	13.00	14.00	-	-	19.00	25.00
Liabilities	5.1%	1,992	1,896	1,766	1,901	3,530	976	977	1,411	1,846	2,280	2,234
Current Liabilities	42.9%	1,489	1,042	810	494	1,388	976	970	-	-	2,217	2,105
Shareholder's Equity	-31.9%	2,761	4,056	5,610	6,936	6,906	7,678	8,405	-	-	-1,628	-
Retained Earnings	-11.2%	-17,218	-15,487	-13,847	-12,054	-9,869	-8,894	-8,143	-	-	-5,795	-4,540
Additional Paid-In Capital	2.2%	19,980	19,543	19,457	18,990	16,776	16,573	16,549	-	-	4,151	2,834
Accumulated Depreciation	-100.0%	-	122	-	-	-	115	-	-	-	-	-
Shares Outstanding	4.5%	16,795	16,069	15,999	15,482	13,654	13,603	10,165	9,292	9,312	9,312	9,292
Float	-	-	-	-	11,713	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Cashflow From Operations	-16.7%	-1,239	-1,062	-1,534	-1,646	-1,337	-679	-1,050	-355	-624	-	-	-
Share Based Compensation	28.8%	111	87.00	38.00	50.00	8.00	47.00	24.00	167	167	-	-	-
Cashflow From Investing	16.4%	101	87.00	-25.85	63.00	-2,953	-	-	-	-	-	-	-
Cashflow From Financing	88.0%	-40.00	-334	-	-139	3,044	-23.32	10,121	-	526	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SHPH Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Revenue
Operating expenses
Research and development	586,104	921,801
General and administrative	324,609	255,355
Legal and professional	474,134	367,624
Total operating expenses	1,384,847	1,544,780
Loss from operations	(1,384,847)	(1,544,780)
Other income (expense)
Interest income	21,453	16,688
Finance fee		(104,245)
Change in fair value of derivative liabilities	197,862	1,241,000
Gain on sale of marketable securities	4,037
Change in fair value of marketable securities	(706)	38,062
Loss on settlement of convertible debt	(71,315)	(18,254)
Total other income (expense)	(346,184)	569,683
Net loss attributable to common stockholders	$ (1,731,031)	$ (975,097)
Weighted average common shares outstanding - basic	16,572,527	13,635,994
Weighted average common shares outstanding - diluted	16,572,527	13,635,994
Net loss per shares - basic	$ (0.10)	$ (0.07)
Net loss per shares - diluted	$ (0.10)	$ (0.07)
Related Party [Member]
Other income (expense)
Interest expense		$ (4,237)
Nonrelated Party [Member]
Other income (expense)
Interest expense	$ (497,515)	$ (599,331)

SHPH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 1,398,628	$ 2,576,416
Prepaid expenses	129,642	114,473
Marketable securities	2,789,251	2,887,215
Accrued interest income	11,964	14,901
Other current assets	81,534
Total Current Assets	4,411,019	5,593,005
Property and equipment, net	22,915	24,827
Operating lease right-of-use asset	319,987	333,904
Total Assets	4,753,921	5,951,736
Current Liabilities
Accrued interest payable	143,676	110,453
Convertible notes payable, net	941,398	595,999
Derivative liability	2,035
Operating lease liability	54,552	52,479
Total Current Liabilities	1,489,217	1,042,237
Convertible notes payable non-current, net		135,089
Derivative liability non-current	214,615	414,512
Operating lease liability non-current	288,602	304,127
Total Liabilities	1,992,434	1,895,965
Stockholders’ Equity
Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding
Common stock, $0.00001 par value; 100,000,000 shares authorized; 16,819,893 and 16,069,320 shares issued and outstanding, respectively	168	161
Additional paid in capital	19,979,962	19,543,222
Accumulated deficit	(17,218,643)	(15,487,612)
Total Stockholders’ Equity	2,761,487	4,055,771
Total Liabilities and Stockholders’ Equity	4,753,921	5,951,736
Nonrelated Party [Member]
Current Liabilities
Accounts payable and accrued expenses	347,556	282,860
Related Party [Member]
Current Liabilities
Accounts payable and accrued expenses		$ 446

About Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.

CEO	Dr. Anatoly Dritschilo M.D.
WEBSITE	shuttlepharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	7

Shuttle Pharmaceuticals Holdings Inc Frequently Asked Questions

What is the ticker symbol for Shuttle Pharmaceuticals Holdings Inc? What does SHPH stand for in stocks?

SHPH is the stock ticker symbol of Shuttle Pharmaceuticals Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Shuttle Pharmaceuticals Holdings Inc (SHPH)?

As of Thu May 16 2024, market cap of Shuttle Pharmaceuticals Holdings Inc is 6.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SHPH stock?

You can check SHPH's fair value in chart for subscribers.

What is the fair value of SHPH stock?

You can check SHPH's fair value in chart for subscribers. The fair value of Shuttle Pharmaceuticals Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Shuttle Pharmaceuticals Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SHPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Shuttle Pharmaceuticals Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether SHPH is over valued or under valued. Whether Shuttle Pharmaceuticals Holdings Inc is cheap or expensive depends on the assumptions which impact Shuttle Pharmaceuticals Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SHPH.